Huntington s disease

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Huntington s disease.php on line 2
Huntington s disease

LE WE PMID CA

Huntington s disease

1233

Huntington Erkrankung

3 Hydroxykynurenine

Autophagy

Fahr s disease

Genetics (Trinucleotide repeat)

Heat shock response

HSF1

Huntington s disease

Hypersexuality

Kynurenic acid

Mitochondria (Dysfunction)

Mitochondria (Mitochondriopathy)

Nervous system (Neurodegeneration)

Organelle migration

Proteasome (BASKET)

Quinolinic acid

Rapamycin

Receptor (PPAR gamma)

Tetrabenazine

Tissue transglutaminase

Wilson s disease

1998 1	Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. [9825166] Can J Psychiatry 43(9): 933-40 (1998)
1998 2	Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. A report of the ANPA Committee on Research. American Neuropsychiatric Association. [9706533] J Neuropsychiatry Clin Neurosci 10(3): 249-66 (1998)
2007 3	Tetrabenazine in the treatment of Huntington's disease. [19381278] Neuropsychiatr Dis Treat 3(5): 545-51 (2007)
2007 4	Neuropsychiatry of Huntington's disease. [17726917] Dialogues Clin Neurosci 9(2): 191-7 (2007)
2005 5	Development of novel therapies for Huntington's disease: hope and challenge. [15663888] Acta Pharmacol Sin 26(2): 129-42 (2005)
2004 6	Huntingtin processing in pathogenesis of Huntington disease. [15456523] Acta Pharmacol Sin 25(10): 1243-9 (2004)
1999 7	Are there multiple pathways in the pathogenesis of Huntington's disease? [10434298] Philos Trans R Soc Lond B Biol Sci 354(1386): 995-1003 (1999)
1982 8	Huntington's chorea. Report of 3 cases and review of the literature. [6461298] Arch Dis Child 57(2): 99-103 (1982)
2007 9	Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients. [17562929] Arch Neurol 64(6): 813-9 (2007)
2004 10	Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington's disease. [15047588] Brain 127(Pt 6): 1219-28 (2004)
1966 11	Huntington's chorea. [16178092] J Med Genet 3(4): 298-314 (1966)
2006 12	Brain imaging and cognitive dysfunctions in Huntington's disease. [16496032] J Psychiatry Neurosci 31(1): 21-9 (2006)
1994 13	Huntington's disease: pathogenesis, diagnosis and treatment. [7528535] J Psychiatry Neurosci 19(5): 359-67 (1994)
2006 14	Multiple pathways contribute to the pathogenesis of Huntington disease. [17173700] Mol Neurodegener 1(-): 19 (2006)
2001 15	Huntington's disease. [11724916] Mol Pathol 54(6): 409-13 (2001)
2004 16	Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. [15717027] NeuroRx 1(2): 263-72 (2004)
2004 17	Huntington's disease genetics. [15717026] NeuroRx 1(2): 255-62 (2004)
2004 18	The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. [15717013] NeuroRx 1(1): 128-38 (2004)
1973 19	Huntington's chorea: a centenary review. [4276170] Postgrad Med J 49(567): 32-45 (1973)
2008 20	Huntington disease models and human neuropathology: similarities and differences. [17978822] Acta Neuropathol 115(1): 55-69 (2008)
2010 21	Impaired mitochondrial trafficking in Huntington's disease. [19591925] Biochim Biophys Acta 1802(1): 62-5 (2010)
2009 22	Mouse models of Huntington's disease and methodological considerations for therapeutic trials. [19362590] Biochim Biophys Acta 1792(6): 506-20 (2009)
2009 23	Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. [18636076] Cell Death Differ 16(1): 46-56 (2009)
2008 24	The ubiquitin-proteasome pathway in Huntington's disease. [18454252] ScientificWorldJournal 8(-): 421-33 (2008)
2011 25	The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. [21285520] J Clin Invest 121(2): 476-83 (2011)
2011 26	Brain networks in Huntington disease. [21285521] J Clin Invest 121(2): 484-92 (2011)
2011 27	Energy deficit in Huntington disease: why it matters. [21285522] J Clin Invest 121(2): 493-9 (2011)
2011 28	Oligonucleotide therapeutic approaches for Huntington disease. [21285523] J Clin Invest 121(2): 500-7 (2011)
2011 29	Shock and awe: unleashing the heat shock response to treat Huntington disease. [21785212] J Clin Invest 121(8): 2972-5 (2011)
2010 30	Molecular mechanisms and potential therapeutical targets in Huntington's disease. [20664076] Physiol Rev 90(3): 905-81 (2010)
2011 31	Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. [21539755] Chang Gung Med J 34(2): 135-52 (2011)
2003 32	Diagnosis of Huntington disease. [14500613] Clin Chem 49(10): 1726-32 (2003)
2010 33	Huntington's disease: pathogenesis to animal models. [20360611] Pharmacol Rep 62(1): 1-14 (2010)
2011 34	Hypersexual features in Huntington's disease. [21731984] Singapore Med J 52(6): e131-3 (2011)
2009 35	Mitochondrial structural and functional dynamics in Huntington's disease. [19394359] Brain Res Rev 61(1): 33-48 (2009)
2008 36	Neuroprotection for Huntington's disease: ready, set, slow. [18394565] Neurotherapeutics 5(2): 226-36 (2008)
2010 37	Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. [20957126] Neuropsychiatr Dis Treat 6(-): 657-65 (2010)
2008 38	Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. [17999380] Histol Histopathol 23(2): 237-50 (2008)
2010 39	Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential. [20964734] J Intern Med 268(5): 419-31 (2010)
2010 40	Dopamine and glutamate in Huntington's disease: A balancing act. [20406248] CNS Neurosci Ther 16(3): 163-78 (2010)
2010 41	Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. [19394403] Prog Neurobiol 90(2): 230-45 (2010)
2007 42	Drug targeting of dysregulated transcription in Huntington's disease. [17379386] Prog Neurobiol 83(4): 249-59 (2007)
2007 43	Transcriptional signatures in Huntington's disease. [17467140] Prog Neurobiol 83(4): 228-48 (2007)
2007 44	The corticostriatal pathway in Huntington's disease. [17169479] Prog Neurobiol 81(5-6): 253-71 (2007)
2009 45	Huntington's disease: silencing a brutal killer. [19786020] Exp Neurol 220(2): 226-9 (2009)
2011 46	Gene therapy in mouse models of huntington disease. [21489966] Neuroscientist 17(2): 153-62 (2011)
2005 47	Knock-in mouse models of Huntington's disease. [16389309] NeuroRx 2(3): 465-70 (2005)
2005 48	The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. [16389308] NeuroRx 2(3): 447-64 (2005)
2009 49	Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. [19622387] Brain Res Bull 80(4-5): 242-7 (2009)
2010 50	The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. [20556492] J Bioenerg Biomembr 42(3): 199-205 (2010)
2010 51	Huntington's disease: a clinical review. [21171977] Orphanet J Rare Dis 5(1): 40 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Huntington s disease.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Huntington s disease.php on line 92